1
Country: Australia
Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for the treatment of pancreatic and ovarian cancer. Focal adhesion kinase (FAK) is expressed in many types of cancer, where it maintains cell viability and stimulates cell growth and migration. Amplia's lead drug candidate, narmafotinib, is a highly selective and potent FAK inhibitor that has shown promising results in pancreatic cancer research. FAK inhibitors act on both the cancer cells themselves and surrounding tissue, making current and future treatments more vulnerable and responsive. Amplia has orphan drug designation, fast-track designation and an open application for pancreatic cancer treatment from the US FDA.
Amplia Therapeutics develops focal adhesion kinase (FAK) inhibitors for the treatment of pancreatic and ovarian cancer. Focal adhesion kinase (FAK) is expressed in many types of cancer, where it maintains cell viability and stimulates cell growth and migration. Amplia's lead drug candidate, narmafotinib, is a highly selective and potent FAK inhibitor that has shown promising results in pancreatic cancer research. FAK inhibitors act on both the cancer cells themselves and surrounding tissue, making current and future treatments more vulnerable and responsive. Amplia has orphan drug designation, fast-track designation and an open application for pancreatic cancer treatment from the US FDA.
2
Country: USA | Funding: $1.3B
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
Fate Therapeutics develops clinical drug candidates for the treatment of autoimmune diseases and cancer using its propriety iPSCs platform (induced pluripotent stem cells). These cell therapies are selectively engineered and provide novel synthetic mechanisms for regulating cellular function. The company utilizes iPSC master cell lines to generate immune system cells, including NK cells, T cells and CD34+ cells and is developing a portfolio of ready-to-use cellular immunotherapy products for the treatment of solid tumors (particularly lung, pancreatic and ovarian cancer). FT819, its first iPSC-derived CAR T-cell product candidate, demonstrates potent, dose-dependent B-cell killing comparable to that of autologous primary CAR T cells in in-vitro cytotoxicity assay using peripheral blood mononuclear cells (PBMCs) in SLE.
3
Country: USA | Funding: $337M
Alaunos Therapeutics develops immunotherapies for cancer treatment using novel TCR-derived T cells. These cell therapies target neoantigens (neoAgs) arising from genomic mutations in solid tumors. The company has developed proprietary, rapid and cost-effective solutions for the delivery of tumor-specific killer T cells. Alaunos' clinical TCR library targets the most common mutations in the KRAS, TP53 and EGFR genes, which are prevalent in gastrointestinal (colon, bile duct, pancreatic), lung and gynecologic (ovarian and endometrial) cancers across a range of different HLA alleles. Company's propriety non-viral Sleeping Beauty transposon/transposase system is used to introduce the TCR gene into the patient's autologous T cells. Alaunos's current pipeline includes clinical trials against lung, colorectal, pancreatic and ovarian cancers.
Alaunos Therapeutics develops immunotherapies for cancer treatment using novel TCR-derived T cells. These cell therapies target neoantigens (neoAgs) arising from genomic mutations in solid tumors. The company has developed proprietary, rapid and cost-effective solutions for the delivery of tumor-specific killer T cells. Alaunos' clinical TCR library targets the most common mutations in the KRAS, TP53 and EGFR genes, which are prevalent in gastrointestinal (colon, bile duct, pancreatic), lung and gynecologic (ovarian and endometrial) cancers across a range of different HLA alleles. Company's propriety non-viral Sleeping Beauty transposon/transposase system is used to introduce the TCR gene into the patient's autologous T cells. Alaunos's current pipeline includes clinical trials against lung, colorectal, pancreatic and ovarian cancers.
4
Country: USA | Funding: $278.1M
InterVenn Biosciences combined the molecular-level resolution of mass spectrometry with the throughput of artificial intelligence to create a unique platform to discover new biomarkers, provide more effective treatments, design precision medicine trials, and pursue novel targets.
InterVenn Biosciences combined the molecular-level resolution of mass spectrometry with the throughput of artificial intelligence to create a unique platform to discover new biomarkers, provide more effective treatments, design precision medicine trials, and pursue novel targets.
5
Country: USA | Funding: $253.7M
Imvax develops personalized immunotherapeutic cancer vaccines against glioblastoma and other solid tumors that are created from the patient's own tumor cells. Imvax's Goldspire platform delivers a combo of patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against the insulin-like growth factor receptor type 1 (IGF-1R). This combination is loaded into implantable, proprietary biodiffusion chambers. This technology is designed to provide both innate and adaptive immune stimulation to overcome the challenges associated with the variability of solid tumors and their ability to suppress the immune system. Imvax is developing a diverse portfolio of drugs against glioblastoma, endometrial cancer, hepatocellular carcinoma, urothelial cancer and ovarian cancer.
Imvax develops personalized immunotherapeutic cancer vaccines against glioblastoma and other solid tumors that are created from the patient's own tumor cells. Imvax's Goldspire platform delivers a combo of patient-derived tumor cells and an antisense oligodeoxynucleotide (IMV-001) against the insulin-like growth factor receptor type 1 (IGF-1R). This combination is loaded into implantable, proprietary biodiffusion chambers. This technology is designed to provide both innate and adaptive immune stimulation to overcome the challenges associated with the variability of solid tumors and their ability to suppress the immune system. Imvax is developing a diverse portfolio of drugs against glioblastoma, endometrial cancer, hepatocellular carcinoma, urothelial cancer and ovarian cancer.
6
Country: Denmark | Funding: $249.6M
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
ADCendo develops antibody-drug conjugates (ADCs) for the treatment of cancers with high unmet medical needs. The company is developing two technologies: ADCE-T02, which combines an optimized monoclonal antibody targeting tissue factor (overexpressed in numerous solid tumor indications) with a next-generation linker and exatecan delivery technology, providing higher efficacy and improved tolerability. The second candidate is ADCE-D01 - a first-in-class ADC targeting uPARAP, an endocytic receptor overexpressed in a wide range of mesenchymal tumors, including soft tissue sarcomas, osteosarcoma, GISTs, mesothelioma and glioblastoma.
7
Country: USA | Funding: $156M
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
With a passion for pioneering breakthrough solutions, we are committed to the advancement of immuno-oncology through the engagement of new and complementary phagocytic pathways that enhance anti-tumor efficacy and selectivity. Acquired by Gilead Sciences
8
Country: UK | Funding: $52M
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
Iksuda Therapeutics is a biotechnology company specializing in the development of next generation biotherapeutics
9
Country: UK | Funding: $50M
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
Enara Bio offers targeted cancer immunotherapies. It is leveraging its platform to discover therapies for ovarian cancer and other solid tumors.
10
Country: USA | Funding: $18.8M
4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification. Although their initial focus is on breast cancer, the company is actively working on developing products for ovarian cancer, cervical cytology, skin cancer, and, in general, around immunotherapy in various cancers.
4D Path uses H&E biopsy images to unveil hidden data instantly providing biomarker profiling and stratification. Although their initial focus is on breast cancer, the company is actively working on developing products for ovarian cancer, cervical cytology, skin cancer, and, in general, around immunotherapy in various cancers.
11
Country: USA | Funding: $15.7M
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.
BioEclipse Therapeutics is a clinical-stage oncology company that develops immuno-oncology therapeutics using its proprietary technology.
12
Country: USA | Funding: $13.8M
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
13
Country: USA | Funding: $120K
Tradewind BioScience is a biotechnology company developing antibody therapeutics for ovarian cancer.
Tradewind BioScience is a biotechnology company developing antibody therapeutics for ovarian cancer.
